A cancer medication’s journey involves more than just reaching the tumor; it must deliver its therapeutic payload effectively, engage with cancer cells, and ideally avoid causing collateral damage. This patent combines several of these challenges into a single biomimetic nanoplatform. Researchers created a material that integrates graphdiyne, a two-dimensional carbon structure, with a copper metal-organic framework (Cu-MOF). The large surface area and abundant π-electrons of graphdiyne help trap copper ions, minimizing free metal ion formation. This structure can catalyze Fenton-like reactions to produce reactive oxygen species (ROS), potentially adding a direct cancer-fighting ability. The platform also carries doxorubicin, a common chemotherapy drug, with reported encapsulation efficiencies of 97.1–99.4%, depending on the formulation. To enhance biocompatibility and targeting, researchers encapsulated the drug-loaded nanomaterial within a cell membrane, creating a biomimetic outer layer. Tests with DU145 prostate cancer cells showed stronger inhibition from the membrane-coated particles, especially at lower doses. Although still at the laboratory stage without clinical validation, this concept marks a significant step in medicine, as it moves from relying solely on drugs to engineering carriers that deliver therapeutic agents, offer additional attack mechanisms, and utilize biological disguises for better targeting.
Giving a cancer drug a carrier, a weapon, and a biological disguise
Patent number: CN 115845082 A
Inventor(s): W. Xie et al.
Citation: W. Xie et al., “一种石墨炔-铜金属有机框架复合纳米材料及其制备方法和仿生材料及其制备方法 [Graphdiyne–copper metal-organic-framework composite nanomaterial, its preparation method, and biomimetic material and preparation method],” China Patent CN 115845082 A, Mar. 28, 2023.
